2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Breast Neoplasms
4
Carcinoma, Squamous Cell
3
Sarcoma
2
Prostatic Neoplasms
2
Carcinoma, Large Cell
2
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrence
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Ewing's Sarcoma Family of Tumors
1
Colorectal Neoplasms
1
Carcinoma, Adenosquamous
1
Carcinoma
1
Breast Diseases
1
Advanced Non-Hematologic Malignancies
1
Advanced Cancer
1
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sunitinib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
figitumumab
×
Clear all
NCT00673049
2013-07-24
NSCLC
Pfizer
Phase 3
Terminated
583 enrolled
11 charts